Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease.
Aberrant detoxification of environmental agents may be the basis for an inherited predisposition to Parkinson's disease. A CYP2D6 genetic marker of the debrisoquine hydroxylase "poor metabolizer" phenotype was found to be significantly increased in Parkinson's disease patients compared to controls, as has been shown in previous studies. Presence of this marker gives an odds ratio of 1.86 for Parkinson's disease (95% confidence interval 1.33-2.39, P < 0.02). For comparison, a CYP1A1 polymorphism, which is not known to be associated with aberrant drug metabolism, showed no association with Parkinson's disease in our study.
Kurth
M C
MC
Division of Neurology, Barrow Neurological Institute, Phoenix, AZ 85013.
Kurth
J H
JH
D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics*; D005787:Gene Frequency; D005819:Genetic Markers; D014644:Genetic Variation; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D008875:Middle Aged; D010300:Parkinson Disease / Q000235:genetics*; D010641:Phenotype
D005819:Genetic Markers; D003577:Cytochrome P-450 Enzyme System